More than 250 British women are taking court action after more than half experienced ruptures in breast implants made by a French company at the centre of a cancer scare, a lawyer said on Wednesday. The women are among up to 50,000 in Britain who have had implants that were manufactured by the now-bankrupt Poly Implant Prothese (PIP). Health officials in France have said the government plans to recommend to 30,000 French women with PIP implants that they have them removed, after eight cases of cancer, mainly breast cancer, were reported.
A lawyer representing more than 250 women in Britain said legal proceedings would start next year, with the complainants making claims against the clinics which carried out the operations to insert the implants. “Over half of these women have suffered ruptured implants and we are also representing other women who are worried by the reports of problems and worried that their implants could rupture eventually,” lawyer Esyllt Hughes told AFP. “We have issued some court proceedings and we expect them to begin in Cardiff next year.” Documents obtained by AFP on Wednesday showed that tens of thousands of women in more than 65 countries, mainly in South America and western Europe, received implants produced by PIP, which ceased trading last year. European authorities sought on Wednesday to head off panic over the scare, saying there was no proof of a link to cancer. France’s health ministry, however, has said there was no “urgent health risk” from the implants and no “causal link” with cancer has yet been proved. An expert report will be released in France on Friday saying whether the implants should be removed.
PIP was shut down and its products banned last year after it was revealed to have been using non-authorised silicone gel that caused abnormally high rupture rates of its implants. Facing financial difficulties, the company, once the world’s third-largest producer of silicone implants, replaced the medical-grade silicone in its implants with industrial-strength material. The Medicines and Healthcare products Regulatory Agency (MHRA) in Britain urged patients not to panic, although it said they may want to consult their surgeons.